AUTHOR=Yan Shuang , Jiang Hua , Gong Li , Pan Lei , Jin Faguang 

TITLE=Diagnostic accuracy of rapid on-site evaluation in subtyping lung cancer via bronchoscopic biopsy

JOURNAL=Frontiers in Oncology

VOLUME=Volume 15 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1566666

DOI=10.3389/fonc.2025.1566666

ISSN=2234-943X

ABSTRACT=BackgroundRapid on-site evaluation (ROSE) is a valuable technique for ensuring the adequacy of specimens during bronchoscopic biopsy; however, its diagnostic utility in lung cancer pathological classification has yet to be comprehensively assessed.ObjectiveTo evaluate the diagnostic utility of ROSE in lung cancer and its accuracy in classifying lung cancer pathological types.MethodsA retrospective analysis was performed on 510 consecutive patients who underwent bronchoscopic biopsy with concurrent ROSE between March and July 2023. ROSE diagnoses were compared with the final pathological diagnoses to access concordance. Sensitivity analyses were conducted to evaluate concordance across cancer subtypes, lesion locations, and patient demographics. The diagnostic accuracy of ROSE in classifying lung cancer subtypes—specifically small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), squamous cell carcinoma (SCC), and adenocarcinoma (AC)—was systematically evaluated.ResultsOverall concordance between ROSE and the final pathological diagnoses was 93.92% (479/510), with near-perfect agreement (k = 0.87, 95% CI: 0.83–0.92). The accuracy of ROSE in distinguishing malignant from benign lesions was significantly lower in central lesions (89.05%) compared to peripheral lesions (95.66%; p = 0.010), and in AC (89.91%) versus SCC (100%; p = 0.0027). ROSE showed high accuracy, sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) for distinguishing SCLC (95.32%, 87.50%, 97.30%, 96.86%, and 89.09%) and NSCLC (92.45%, 92.34%, 92.86%, 75.36%, and 98.09%). For SCC and AC, they were 84.91%, 89.32%, 80.73%, 88.89%, and 81.42% vs 79.72%, 69.72%, 90.29%, 73.81%, and 88.37%, respectively.ConclusionROSE effectively differentiates benign from malignant lesions and accurately classifies SCLC and NSCLC during bronchoscopic biopsy. While useful for preliminary subtyping of SCC and AC, its reduced sensitivity for AC and challenges in central lesion evaluation limit its utility as a standalone diagnostic tool. ROSE remains critical for optimizing biopsy workflows and reducing repeat procedures.